Modality
mAb
MOA
KRASG12Di
Target
FGFR
Pathway
mTOR
BCCSCLC
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
~Aug 2020
→ ~Nov 2021
Phase 3
~Feb 2022
→ ~May 2023
NDA/BLA
Aug 2023
→ Nov 2026
NDA/BLACurrent
NCT07892630
2,445 pts·BCC
2023-08→2026-11·Terminated
2,445 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-248mo awayPh3 Readout· BCC
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-11-24 · 8mo away
BCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07892630 | NDA/BLA | BCC | Terminated | 2445 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| DAW-5540 | Day One Bio | Phase 2 | AHR | |
| AKR-4818 | Akero | Approved | CD20 |